GILD250509C106000
- 0.03
- -0.01-25.00%
Gilead Sciences Newsroom
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $110
TD Cowen Keeps Their Buy Rating on Gilead Sciences (GILD)
Argus Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $120
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $117
Gilead Sciences (GILD) Gets a Buy From Mizuho Securities
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110
Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects
BofA Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $126
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Gilead Sciences: Strong Market Position and Positive Long-Term Outlook Justify Buy Rating
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $135
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating
Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating
Gilead Sciences Analyst Ratings
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $125 to $140
Jefferies Keeps Their Buy Rating on Gilead Sciences (GILD)